A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT ID: NCT06405425

Last Updated: 2025-05-07

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-29
• Study Completion Date: 2026-05-31

Brief Summary

This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.

Conditions

Urothelial Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BL-B01D1 + PD-1

Participants receive BL-B01D1 + PD-1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.

Group Type: EXPERIMENTAL

BL-B01D1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

PD-1

Intervention Type: DRUG

Administration by intravenous infusion for a cycle of 3 weeks.

Interventions

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

PD-1

Administration by intravenous infusion for a cycle of 3 weeks.

Intervention Type: DRUG

Other Intervention Names

iza-bren; izalontamab brengitecan; BMS-986507

Eligibility Criteria

Inclusion Criteria

1. All subjects voluntarily participated in the study and signed informed consent;

2. Male or female aged ≥18 years and ≤75 years;

3. Expected survival time ≥3 months;

4. ECOG 0-1;

5. Unresectable locally advanced or metastatic urothelial carcinoma confirmed by histopathology and/or cytology;

6. Participants should not have received previous systemic therapy for locally advanced or metastatic urothelial cancer;

7. A biopsy sample of archived tumor tissue or metastatic urothelial carcinoma must be available within 3 years for PD-L1 and other testing;

8. At least one measurable lesion meeting the RECIST v1.1 definition was required;

9. The level of organ function must meet the requirements on the premise that blood transfusion and the use of any cell growth factors and/or platelet-raising drugs are not allowed within 14 days before the first dose;

10. Previous treatment-related toxicity returned to ≤ grade 1 defined by NCI-CTCAE v5.0;

11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, the serum or urine pregnancy test must be negative, and the patient must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria

1. Prior ADC recipients with TOPI inhibitors as toxin;

2. Palliative radiotherapy within 2 weeks before the first dose;

3. Prior immunotherapy with grade ≥3 irAE or grade ≥2 immune-related myocarditis;

4. Use of an immunomodulatory drug within 14 days before the first dose of study drug;

5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened;

6. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;

7. Active autoimmune and inflammatory diseases;

8. Receiving &gt before the first dose; Long-term systemic corticosteroid therapy with prednisone 10mg/d;

9. Other malignant tumors that progressed or required treatment within 5 years before the first dose;

10. Presence of: a) poorly controlled diabetes mellitus before starting study treatment; b) severe complications associated with diabetes mellitus; c) a glycated hemoglobin level of 8% or more; d) hypertension poorly controlled by two antihypertensive drugs; e) history of hypertensive crisis or hypertensive encephalopathy;

11. History of ILD, current ILD, or suspected ILD;

12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;

13. Screening for unstable thrombotic events requiring therapeutic intervention within the preceding 6 months; Infusion-related thrombosis was excluded;

14. Patients with active central nervous system metastases;

15. Patients with massive or symptomatic effusions or poorly controlled effusions;

16. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or allergic to any excipients of the test drug;

17. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

18. HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

19. Serious infection within 4 weeks before the first dose of study drug; Signs of pulmonary infection or active pulmonary inflammation within 4 weeks;

20. Participated in another clinical trial within 4 weeks before the first dose;

21. Patients with superior vena cava syndrome should not be rehydrated;

22. Have a history of psychotropic substance abuse with an inability to quit or a history of severe neurological or psychiatric illness;

23. Imaging examination showed that the tumor had invaded or wrapped the large thoracic vessels;

24. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;

25. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;

26. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose;

27. Other circumstances considered by the investigator to be inappropriate for participation in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: collaborator

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dingwei Ye

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Sa Xiao, PHD

Role: CONTACT

xiaosa@baili-pharm.com

+8615013238943

Facility Contacts

Dingwei Ye

Role: primary

Other Identifiers

BL-B01D1-204-03

Identifier Type: -

Identifier Source: org_study_id